Core Laboratories (CLB) Aandelenoverzicht
Core Laboratories Inc. levert diensten en producten voor reservoirbeschrijving en productieverbetering aan de olie- en gasindustrie in de Verenigde Staten en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 3/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
CLB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Core Laboratories Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$13.67 |
| 52 Week Hoogtepunt | US$20.36 |
| 52 Week Laag | US$9.72 |
| Bèta | 1.0 |
| 1 maand verandering | -2.84% |
| 3 maanden verandering | -20.89% |
| 1 Jaar Verandering | 27.16% |
| 3 jaar verandering | -47.24% |
| 5 jaar verandering | -71.26% |
| Verandering sinds IPO | 355.67% |
Recent nieuws en updates
Narratiefupdate • May 23
CLB: Middle East Disruptions Will Shape Undervalued Shares And Future P/E
Analysts have kept their $22.00 price target for Core Laboratories unchanged, citing updated assumptions that include a slightly higher discount rate and revenue growth outlook, along with a marginally lower profit margin and P/E expectation. What's in the News Core Laboratories revised its first quarter 2026 guidance, now expecting revenue between US$119,000,000 and US$123,000,000, operating income ex-items of US$5,700,000 to US$7,100,000, and EPS ex-items of US$0.05 to US$0.07, citing impacts from geopolitical conflict in the Middle East, client project delays, travel limits, and supply chain disruptions (Key Developments).
Narratiefupdate • Apr 28
CLB: Fair Outlook Balances Middle East Disruptions And Governance Changes
Analysts have raised their price target on Core Laboratories from about $14.00 to roughly $16.33, citing updated views on fair value, discount rate, revenue growth, profit margins, and future P/E assumptions. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000 and EPS, ex items, of US$0.05 to US$0.07 for the period (Key Developments).Narratiefupdate • Apr 14
CLB: Fair Value View Will Rely On Middle East Risk And P/E Assumptions
Analysts have raised their price target on Core Laboratories from $18 to $22, citing updated assumptions around revenue growth, profit margins, and a slightly higher future P/E multiple as key drivers of the change. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000, operating income ex items of US$5,700,000 to US$7,100,000, and Earnings Per Share ex items of US$0.05 to US$0.07 (Key Developments).Seeking Alpha • Mar 26
Core Laboratories: Profit Margins Are Too Small To Get Excited About
Summary Core Laboratories remains a HOLD due to persistently low profit margins and unattractive free cash flow yields. Recent Middle East disruptions have significantly impacted CLB’s higher-margin Reservoir Description segment, prompting a downward revision of Q1 EPS guidance. CLB’s capital allocation will continue with a 50/50 split between debt reduction and shareholder returns, targeting leverage below 1.0x. The current valuation at 14x EBITDA is not justified given flat revenues, low margins, and increased operational risks. The stock is valued at low single digit free cash flow yields. Read the full article on Seeking AlphaRecent updates
Narratiefupdate • May 23
CLB: Middle East Disruptions Will Shape Undervalued Shares And Future P/E
Analysts have kept their $22.00 price target for Core Laboratories unchanged, citing updated assumptions that include a slightly higher discount rate and revenue growth outlook, along with a marginally lower profit margin and P/E expectation. What's in the News Core Laboratories revised its first quarter 2026 guidance, now expecting revenue between US$119,000,000 and US$123,000,000, operating income ex-items of US$5,700,000 to US$7,100,000, and EPS ex-items of US$0.05 to US$0.07, citing impacts from geopolitical conflict in the Middle East, client project delays, travel limits, and supply chain disruptions (Key Developments).Narratiefupdate • Apr 28
CLB: Fair Outlook Balances Middle East Disruptions And Governance Changes
Analysts have raised their price target on Core Laboratories from about $14.00 to roughly $16.33, citing updated views on fair value, discount rate, revenue growth, profit margins, and future P/E assumptions. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000 and EPS, ex items, of US$0.05 to US$0.07 for the period (Key Developments).Narratiefupdate • Apr 14
CLB: Fair Value View Will Rely On Middle East Risk And P/E Assumptions
Analysts have raised their price target on Core Laboratories from $18 to $22, citing updated assumptions around revenue growth, profit margins, and a slightly higher future P/E multiple as key drivers of the change. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000, operating income ex items of US$5,700,000 to US$7,100,000, and Earnings Per Share ex items of US$0.05 to US$0.07 (Key Developments).Seeking Alpha • Mar 26
Core Laboratories: Profit Margins Are Too Small To Get Excited About
Summary Core Laboratories remains a HOLD due to persistently low profit margins and unattractive free cash flow yields. Recent Middle East disruptions have significantly impacted CLB’s higher-margin Reservoir Description segment, prompting a downward revision of Q1 EPS guidance. CLB’s capital allocation will continue with a 50/50 split between debt reduction and shareholder returns, targeting leverage below 1.0x. The current valuation at 14x EBITDA is not justified given flat revenues, low margins, and increased operational risks. The stock is valued at low single digit free cash flow yields. Read the full article on Seeking AlphaNarratiefupdate • Jan 26
CLB: Fair Value View Will Rely On Stable Margins And P/E Assumptions
Analysts held their price target on Core Laboratories steady at US$18.00, citing only small tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their overall view of the company. Valuation Changes Fair Value: Held steady at US$18.00, indicating no change in the core valuation output.Narratiefupdate • Jan 11
CLB: Fair Value View Will Rely On Stabilizing Margins And EPS
Analysts kept their Core Laboratories fair value estimate around $18.00. The updated price target mainly reflects slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E rather than a major shift in their view of the stock.Narratiefupdate • Dec 14
CLB: Future Earnings And Margins Are Expected To Gradually Stabilize
Analysts have modestly reduced their price target on Core Laboratories by 1 dollar to 18 dollars. This reflects a slightly lower fair value despite improved expectations for revenue growth, profit margin, and a less demanding future price to earnings multiple.Analyseartikel • Nov 21
A Look At The Fair Value Of Core Laboratories Inc. (NYSE:CLB)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$14.45 Core...Narratiefupdate • Sep 10
Middle East And Asia Pacific Markets Will Secure Energy Success
With both the discount rate and future P/E ratio remaining essentially stable, the consensus analyst price target for Core Laboratories was unchanged at $14.00. What's in the News Core Laboratories issued third quarter 2025 guidance, expecting revenue of $127.5–134.5 million, operating income of $13.6–16.2 million, operating margin of approximately 11%, and EPS of $0.18–0.22.Analyseartikel • Sep 10
Core Laboratories Inc.'s (NYSE:CLB) 25% Jump Shows Its Popularity With Investors
Core Laboratories Inc. ( NYSE:CLB ) shareholders would be excited to see that the share price has had a great month...Analyseartikel • Jul 24
We Think Core Laboratories (NYSE:CLB) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Jul 03
Core Laboratories (NYSE:CLB) Will Be Hoping To Turn Its Returns On Capital Around
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...Analyseartikel • Jun 12
Is There An Opportunity With Core Laboratories Inc.'s (NYSE:CLB) 49% Undervaluation?
Key Insights The projected fair value for Core Laboratories is US$23.89 based on 2 Stage Free Cash Flow to Equity Core...Analyseartikel • Apr 04
Core Laboratories Inc.'s (NYSE:CLB) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 20x Core Laboratories Inc. ( NYSE:CLB ) may be sending bearish signals at...Analyseartikel • Jan 21
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 27% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$27.00 Core...Analyseartikel • Jan 03
Core Laboratories Inc. (NYSE:CLB) Not Lagging Market On Growth Or Pricing
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...Analyseartikel • Dec 09
Returns On Capital At Core Laboratories (NYSE:CLB) Paint A Concerning Picture
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...Analyseartikel • Nov 12
Is Core Laboratories (NYSE:CLB) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Nieuw narratief • Sep 24
New Product Launches And Deleveraging To Propel Growth Amidst Geopolitical Challenges
Diversification in geographical markets and services strengthens revenue by expanding market presence and targeting regions with growing demand.Analyseartikel • Sep 19
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 38% Discount?
Key Insights The projected fair value for Core Laboratories is US$29.58 based on 2 Stage Free Cash Flow to Equity...Analyseartikel • Aug 14
What You Can Learn From Core Laboratories Inc.'s (NYSE:CLB) P/E
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...Analyseartikel • Jul 15
We Think Core Laboratories (NYSE:CLB) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Jun 25
These Return Metrics Don't Make Core Laboratories (NYSE:CLB) Look Too Strong
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...Analyseartikel • May 02
It's Unlikely That Core Laboratories Inc.'s (NYSE:CLB) CEO Will See A Huge Pay Rise This Year
Key Insights Core Laboratories' Annual General Meeting to take place on 8th of May Salary of US$886.9k is part of CEO...Analyseartikel • Mar 26
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 25% Discount?
Key Insights The projected fair value for Core Laboratories is US$22.93 based on 2 Stage Free Cash Flow to Equity Core...Analyseartikel • Mar 02
Why We're Not Concerned About Core Laboratories Inc.'s (NYSE:CLB) Share Price
Core Laboratories Inc.'s ( NYSE:CLB ) price-to-earnings (or "P/E") ratio of 19.8x might make it look like a sell right...Rendement voor aandeelhouders
| CLB | US Energy Services | US Markt | |
|---|---|---|---|
| 7D | -3.9% | -5.6% | 1.6% |
| 1Y | 27.2% | 80.9% | 28.5% |
Rendement versus industrie: CLB presteerde slechter dan de US Energy Services -sector, die het afgelopen jaar een rendement van 80.9 % opleverde.
Rendement versus markt: CLB presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 28.5 % opleverde.
Prijsvolatiliteit
| CLB volatility | |
|---|---|
| CLB Average Weekly Movement | 7.6% |
| Energy Services Industry Average Movement | 7.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stabiele aandelenkoers: CLB heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van CLB is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1936 | 3,300 | Larry Bruno | www.corelab.com |
Core Laboratories Inc. levert diensten en producten voor reservoirbeschrijving en productieverbetering aan de olie- en gasindustrie in de Verenigde Staten en internationaal. Het bedrijf is actief in de segmenten Reservoirbeschrijving en Productieverbetering. Het segment Reservoirbeschrijving omvat de karakterisering van petroleumreservoirgesteente en reservoirvloeistofmonsters om de productie te verbeteren en het herstel van ruwe olie en aardgas uit de reservoirs van haar klanten te verbeteren.
Core Laboratories Inc. Samenvatting
| CLB fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$630.14m |
| Inkomsten(TTM) | US$29.03m |
| Inkomsten(TTM) | US$524.73m |
21.7x
Koers/Winstverhouding1.2x
P/S-verhoudingIs CLB overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CLB resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$524.73m |
| Kosten van inkomsten | US$420.19m |
| Brutowinst | US$104.54m |
| Overige uitgaven | US$75.51m |
| Inkomsten | US$29.03m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 0.63 |
| Brutomarge | 19.92% |
| Nettowinstmarge | 5.53% |
| Schuld/Eigen Vermogen Verhouding | 41.6% |
Hoe presteerde CLB op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
0.3%
Huidig dividendrendement6%
UitbetalingsratioBetaalt CLB een betrouwbaar dividend?
Zie CLB dividendgeschiedenis en benchmarks| Core Laboratories dividenddata | |
|---|---|
| Ex Dividend Datum | May 11 2026 |
| Betaaldatum dividend | Jun 01 2026 |
| Dagen tot Ex-dividend | 21 days |
| Dagen tot dividendbetaaldatum | 0 days |
Betaalt CLB een betrouwbaar dividend?
Zie CLB dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/31 17:13 |
| Aandelenkoers aan het einde van de dag | 2026/05/29 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Core Laboratories Inc. wordt gevolgd door 30 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| James West | Barclays |
| Nicholas Green | Bernstein |
| Saurabh Pant | BofA Global Research |